Market revenue in 2023 | USD 8.3 million |
Market revenue in 2030 | USD 13.9 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Mrna reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 32.53% in 2023. Horizon Databook has segmented the Australia cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
Rising research for advancing cell reprogramming applications by companies and research institutes is boosting the cell reprogramming market in Australia. For instance, according to an article published by the Telethon Kids Institute in August 2023, Australian scientists have devised a new technique to reset the memory of reprogrammed human cells, enhancing their resemblance to embryonic stem cells.
This breakthrough holds substantial implications for treating various severe diseases. The application of embryonic stem cells in medicine poses ethical and practical challenges, and reprogramming adult cells into functionally equivalent iPS cells offers a vital alternative.
This approach empowers scientists to advance stem cell therapies without the ethical concerns associated with embryonic stem cells, providing a promising avenue for medical advancements.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into Australia cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account